DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. (Q30408029)

21 June 2017

DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. (English)

1 reference

21 June 2017

1 reference

0 references

Franco Lori

1

1 reference

21 June 2017

1 October 2011

1 reference

Expert Review of Vaccines

21 June 2017

1 reference

21 June 2017

10

1 reference

21 June 2017

10

1 reference

21 June 2017

1371-1384

1 reference

An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction

21 June 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Survival of persons with and without HIV infection in Denmark, 1995-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Therapeutic HIV vaccines show promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Overview of vaccines and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

The rational design of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

A therapeutic dendritic cell-based vaccine for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Genetic immunization is a simple method for eliciting an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Induction of immune responses by DNA vaccines in large animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

DNA vaccines: developing new strategies to enhance immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Plasmid DNA and viral vector-based vaccines for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

DNA vaccines: developing new strategies against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

DNA vaccines against cancer come of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Rational development of a stable liquid formulation for nanomedicine products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

DermaVir: a novel topical vaccine for HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Targeting dendritic cells with biomaterials: developing the next generation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Biophysical characterization of PEI/DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Immunization with DNA through the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Localization dose and time of antigens determine immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.118

21 January 2018

Identifiers

DOI

10.1586/ERV.11.118

1 reference

21 June 2017

1 reference

PubMed ID

21988301